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CLINICAL REPORT
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Summary Acral myxoinﬂammatory ﬁbroblastic sarcoma is a rare low-grade malignant soft
tissue tumor, usually observed in the extremities of middle-aged patients. We report a case
involving the third ﬁnger of the left hand of a middle-aged man. The tumor showed a nodular
architecture, with cellular areas, occasional foci of hyalinized ﬁbrosis, and hypocellular areasMyxoid;
Bizarre cells
with a myxoid background. Various neoplastic cells were identiﬁed including spindled or rounded
epithelioid cells and occasional bizarre giant cells, morphologically mimicking ganglion cells.
Tumor cells were strongly immunoreactive for vimentin and variably positive for CD68 and CD34.
The tumor was completely removed, without further treatment.
© 2010 Published by Elsevier Masson SAS.
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Acral myxoinﬂammatory ﬁbroblastic sarcoma (AMFS) is a
recently identiﬁed low-grade soft tissue tumor, mainly
affecting the extremities of middle-aged subjects. We
report a case in a middle-aged man, highlighting the diag-
nostic criteria for this rare tumor, which it is important not
to overlook so as to be able to perform optimal surgical
exeresis.
Clinical observationA 51-year-old male, with no particular history, consulted for
sensitive swelling of the inner side of the third ﬁnger of the
left hand, which had been evolving for 6 months. Clinically,
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doi:10.1016/j.otsr.2009.11.018he lesion was nodular, soft, without local inﬂammatory
igns or satellite adenopathy.
Coronal short T1 inversion recovery magnetic resonance
maging (STIR MRI) revealed isolated 3 cm tumefaction of the
eft third ray P1 soft tissue with normal bone medulla, with
igh contrast uptake, inﬁltration of surrounding tissue and
rosion of the facing bone (Fig. 1). Biopsy exeresis enabled
iagnosis, leading to amputation of the ﬁnger, ensuring the
ealthy status of the stump. Evolution was fair at 10 months’
ollow-up.
natomopathology
he lesion was macroscopically nodular, without capsule,
nd of a yellowish white color (Fig. 2).
The microscopic aspect was lobular, poorly contoured
nd featuring often abrupt transition between dense cel-
ular areas with an edematous or hyalinized background and
ypocellular areas with a myxoid background. The tumor
.
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Figure 3 Ganglion-like giant cells (× 100).igure 1 Magnetic resonance imaging (MRI) showing homoge-
eous inﬁltrating lesion.
ells were of medium to large size, and of two types: bizarre
ells of a ganglion-like aspect (Fig. 3) and lipoblast-like vac-
olated cells (Fig. 4). The mitosis index was low, at 3 per
0 high enlargement ﬁelds. A mixed inﬂammatory inﬁltrate
f variable density associated lymphocytes, plasmocytes,
nd polynuclear eosinophils and neutrophils (Fig. 5). Ves-
els were numerous outside the myxoid areas, with smooth
nd thick muscular walls. There was no necrosis.
Tumor cells were strongly immunoreactive for vimentin
nd variably positive for CD68 and CD34. The tumor was
ompletely removed, without further treatment.
Immunohistochemistry showed strong and diffuse
mmunoreactivity for anti-vimentin antibodies and variable
mmunoreactivity for anti-CD68 and anti-CD34 antibodies.
he tumor cells expressed no smooth muscle actin.
Figure 2 Nodular lesion.
Figure 4 Lipoblast-like cells (× 100).
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SFigure 5 Mixed inﬂammatory inﬁltrate (× 100).
iscussionMFS was ﬁrst described in 1998, almost simultaneously by
hree different teams, under three different names [1—3].
ome hundred cases have since been reported [3—7].
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[Acral myxoinﬂammatory ﬁbroblastic sarcoma
It is a rare, low-grade sarcoma, mainly affecting middle-
aged persons, and located in the extremities (ﬁngers and
hands, for 75% of cases). Clinically, the lesion is inﬁltrating,
pain-free and of slow evolution.
Macroscopically, the tumor ranges in size from 1.5 to
18 cm, is generally well contoured, lobular, yellowish in color
and sometimes mucoid. Occasionally, areas of necrosis and
hemorrhage are found [8,9].
Microscopically, there are three main characteristics
[1,3,7,10,11]:
• a somewhat multinodular overall architecture, alternat-
ing densely cellular and myxoid hypocellular areas;
• mixed inﬂammatory inﬁltrate;
• bizarre giant and lipoblast-like cells.
The present case meets these microscopy criteria.
The immunohistochemical phenotype is non-speciﬁc: the
tumor cells express vimentin (in all cases), CD68 (in 66%
of cases), CD34 (in 28%), smooth muscle actin (in 6%) and
cytokeratin (KL1) (in 11%). They do not express epithelial
membrane antigen, protein S100, desmin, CD15, HMB45,
CD45, or Epstein-Barr virus (EBV) latent membrane protein
(LMP1) [3,7,10].
The physiopathogenesis of AMFS is poorly understood.
No infectious agent has been identiﬁed. PCR for EBV,
performed in a few cases, indicated only latent rather
than active infection [1,3,7]. Immunohistochemistry with
anti-cytomegalovirus (CMV) and/or anti-EBV antibodies,
performed in several series, also proved negative [1,3,8,11].
A cytogenetic study of a single case found a complex kary-
otype with reciprocal t(1;10)(p22, q24) translocation, and
three and 13 deletion [3,6].
From the clinician’s point of view, differential diagno-
sis is between infectious or chronic inﬂammatory process
and benign tumor such as nodular fasciitis, tendon giant
cell tumor and synovial pseudocyst. From the pathologist’s
point of view, differential diagnosis depends on the predomi-
nance of inﬂammatory, myxoid and bizarre cell components,
and is between non-tumoral lesions such as inﬂammatory
pseudo-tumor (bizarre giant cells being sometimes difﬁ-
cult to identify in the inﬂammatory inﬁltrate) and tumoral
lesions such as giant cell tumor, inﬂammatory ﬁbrosarcoma,
inﬂammatory myoﬁbroblastic tumor or myxoﬁbrosarcoma
[1,3,7,8,10,11]. Myxoﬁbrosarcoma differs from AMFS in its
proximal location and it is more aggressive, pleomorphic and
storiform character [4,7]. Alternative diagnoses can often
be ruled out by the discovery of bizarre giant cells and by
the tumor location [1,7]. In practice, sarcoma of the extrem-
ities is rare, and mainly limited to epithelioid sarcoma,
synovialosarcoma and clear-cell sarcoma [1,7,12].
Local recurrence ranges from 22% [1,3,7] to 67% [3,7,10],
at a median of 4 to 10 months, depending on the series.
Only three cases of metastasis have been reported: two gan-
glionic [3,4,10] and one pulmonary [3,10], the latter not
demonstrated on histology. No associated deaths have been
reported.
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Treatment consists in full surgical exeresis, checking the
ealthy status of the remaining edges [9].
onclusion
MFS is a rare low-grade tumor associated with virtually no
etastasis, but liable to recurrence. Prognosis depends on
nitial surgical management, which should consist in com-
lete exeresis, despite the probable functional impact.
Several clinical issues remain unresolved, especially
egarding recurrence and metastasis rates and intervals.
urther research on these lines is underway to assess results
ore clearly.
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